*Safety and efficacy of in pediatric patients with asthma aged 5 to 11 years have been established in 3 clinical trials. *In those trials, 234 subjects were administered Arnuity Ellipta 50 mcg once daily. Patients aged 5 to 11 years demonstrated safety and efficacy results similar to those observed in subjects aged 12 years and older. *Safety and efficacy have not been established in pediatric patients aged younger than 5 years. *Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to children and adolescents. *Information on dosing, adverse reactions, PK parameters, and clinical trials.
|